Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Restructuring Costs (2016 - 2018)

Historic Restructuring Costs for Cardiff Oncology (CRDF) over the last 3 years, with Q3 2018 value amounting to $421351.0.

  • Cardiff Oncology's Restructuring Costs rose 100667.71% to $421351.0 in Q3 2018 from the same period last year, while for Sep 2019 it was $421351.0, marking a year-over-year decrease of 6300.49%. This contributed to the annual value of $664686.0 for FY2018, which is 6942.92% down from last year.
  • Per Cardiff Oncology's latest filing, its Restructuring Costs stood at $421351.0 for Q3 2018, which was up 100667.71% from $243335.0 recorded in Q2 2018.
  • Over the past 5 years, Cardiff Oncology's Restructuring Costs peaked at $1.7 million during Q1 2017, and registered a low of -$46472.0 during Q3 2017.
  • Moreover, its 3-year median value for Restructuring Costs was $421351.0 (2018), whereas its average is $514128.7.
  • Per our database at Business Quant, Cardiff Oncology's Restructuring Costs tumbled by 4000.15% in 2017 and then soared by 649345.77% in 2018.
  • Cardiff Oncology's Restructuring Costs (Quarter) stood at $790438.0 in 2016, then crashed by 40.0% to $474251.0 in 2017, then fell by 11.15% to $421351.0 in 2018.
  • Its Restructuring Costs was $421351.0 in Q3 2018, compared to $243335.0 in Q2 2018 and $474251.0 in Q4 2017.